Developer docs
API playgroundTry for free, no card

Search company profiles

Atypical Ventures

Full company profile

uuid00069xc

Namestring
Atypical Ventures
Legal namestring
Atypical Ventures
Websiteurl
atypical.com
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital investing, pre-seed funding, seed stage capital, frontier technology investing, startup equity investment
Industry1 code
1Early-Stage Venture Capital (Pre-Seed/Seed)
CodeFSANAAAAPrimaryYes
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles1 record
Revenue model1 record
1Venture Capital Returns
TypeLicensing Royalties
Description

Typical VC model investing $500K-$1M at pre-seed and seed stages in technical founders across atoms, bits, and cells. Returns generated through exits via acquisitions and IPOs.

atypical.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Pre-seed to Seed investment
ModelOtherBilling cadenceMulti-year contract
Notes

$500K–$1M investment tickets for early-stage founders

atypical.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Atypical Ventures is a venture capital firm that invests $500K–$1M per company at the pre-seed and seed stages in technical founders building frontier technology companies across three domains: atoms (physical/hardware), bits (software/AI), and cells (biotech). Beyond capital, the firm provides hands-on value-add support including go-to-market pressure testing, narrative sharpening, and ongoing execution help, typically backing roughly ten founders per fund.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Atypical Ventures is a venture capital firm based in San Carlos, California, that invests $500K–$1M at pre-seed and seed stages. The firm targets frontier technology founders across three broad domains: atoms (physical/hardware), bits (software/AI), and cells (biotech). Their investment strategy centers on non-consensus opportunities, backing technical founders with empathy who are building solutions to hard problems that outlive hype cycles. The firm operates as a conviction-based investor, typically backing a small handful of founders per fund rather than pursuing volume. Their portfolio examples include Atomic Alchemy (nuclear fuel/acquired by Oklo), Exa (AI-native search), and Parallel Bio (human-first drug discovery platform).

Product and service3 records
1Pre-Seed Venture Investment ($500K–$1M ticket)
CategoryVenture Capital Investment
Description

Equity capital investment of $500K–$1M made at the pre-seed stage in technical founders building frontier technology companies across atoms (physical), bits (software/AI), and cells (biotech), accompanied by hands-on strategic support.

2Seed-Stage Venture Investment ($500K–$1M ticket)
CategoryVenture Capital Investment
Description

Equity capital investment of $500K–$1M made at the seed stage in technical founders building frontier technology companies across atoms, bits, and cells, paired with conviction-driven, high-engagement partnership.

3Portfolio Founder Value-Add Support
CategoryInvestor Value-Add Services
Description

Hands-on operational support provided to portfolio companies beyond capital, including go-to-market pressure testing, narrative sharpening, building talent engines, and ongoing execution assistance across the life of the investment.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment42 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Atypical Ventures

Venture Capitalatypical.com

Atypical Ventures firmographics

Firmographics
Name
Atypical Ventures
Legal name
Atypical Ventures
Website
https://atypical.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Atypical Ventures industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro primary industry
Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA)

Keywords

  • Venture capital investing
  • Pre-seed funding
  • Seed stage capital
  • Frontier technology investing
  • Startup equity investment

Where Atypical Ventures is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Atypical Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Venture Capital Returns: Typical VC model investing $500K-$1M at pre-seed and seed stages in technical founders across atoms, bits, and cells. Returns generated through exits via acquisitions and IPOs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPre-seed to Seed investment

Distribution channels1 record

Marketing channels3 records

Atypical Ventures product offering

Product offering

Core offering

Atypical Ventures is a venture capital firm that invests $500K–$1M per company at the pre-seed and seed stages in technical founders building frontier technology companies across three domains: atoms (physical/hardware), bits (software/AI), and cells (biotech). Beyond capital, the firm provides hands-on value-add support including go-to-market pressure testing, narrative sharpening, and ongoing execution help, typically backing roughly ten founders per fund.

Product overview

Atypical Ventures is a venture capital firm based in San Carlos, California, that invests $500K–$1M at pre-seed and seed stages. The firm targets frontier technology founders across three broad domains: atoms (physical/hardware), bits (software/AI), and cells (biotech). Their investment strategy centers on non-consensus opportunities, backing technical founders with empathy who are building solutions to hard problems that outlive hype cycles. The firm operates as a conviction-based investor, typically backing a small handful of founders per fund rather than pursuing volume. Their portfolio examples include Atomic Alchemy (nuclear fuel/acquired by Oklo), Exa (AI-native search), and Parallel Bio (human-first drug discovery platform).

Differentiator

Problem solved

Functional benefit

Products and services

  • Pre-Seed Venture Investment ($500K–$1M ticket) Equity capital investment of $500K–$1M made at the pre-seed stage in technical founders building frontier technology companies across atoms (physical), bits (software/AI), and cells (biotech), accompanied by hands-on strategic support.
  • Seed-Stage Venture Investment ($500K–$1M ticket) Equity capital investment of $500K–$1M made at the seed stage in technical founders building frontier technology companies across atoms, bits, and cells, paired with conviction-driven, high-engagement partnership.
  • Portfolio Founder Value-Add Support Hands-on operational support provided to portfolio companies beyond capital, including go-to-market pressure testing, narrative sharpening, building talent engines, and ongoing execution assistance across the life of the investment.

Companies that use Atypical Ventures

Customer profile

Segments2 records

Ideal customer profiles1 record

Atypical Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Atypical Ventures partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Atypical Ventures competitors and assessment

Company assessment

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Atypical Ventures social profiles

Digital presence

Atypical Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Atypical Ventures leadership team

Management profile

Number of profiles

Profiles1 record

Atypical Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Atypical Ventures M&A and investment

M&A and investment

M&A

Investments42 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atypical Ventures

What does Atypical Ventures do?

Atypical Ventures is a venture capital firm that invests $500K–$1M per company at the pre-seed and seed stages in technical founders building frontier technology companies across three domains: atoms (physical/hardware), bits (software/AI), and cells (biotech). Beyond capital, the firm provides hands-on value-add support including go-to-market pressure testing, narrative sharpening, and ongoing execution help, typically backing roughly ten founders per fund.

Is Atypical Ventures a public or private company?

Atypical Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Atypical Ventures founded?

Atypical Ventures was founded in 2019. It employs 1 to 10 people.

Where is Atypical Ventures based?

Atypical Ventures is headquartered in New York, United States, in the North America region.

How does Atypical Ventures make money?

One revenue line is on record: venture Capital Returns.

Does Atypical Ventures have an API?

No public API is recorded for Atypical Ventures.

What industry is Atypical Ventures in?

Atypical Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAA, Early-Stage Venture Capital (Pre-Seed/Seed). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineShennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12M in financing from multiple investors, bringing its total to $25M. The company appointed Cyril Konto as CEO, with founder Li Sun transitioning to President and CTO. The funds will advance three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma toward clinical development.Pulse 2.0Shennon Biotechnologies Raises $12 Million, Names Cyril Konto As CEO, And Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12 million in financing and appointed Cyril Konto as CEO, bringing total capital to $25 million. The funds will advance three T-cell engager programs for small-cell lung cancer, ovarian cancer, and hepatocellular carcinoma. The company plans to advance a development candidate toward an IND filing within two years.BioSpaceShennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12M in financing and appointed Cyril Konto as CEO, with founder Li Sun moving to President and CTO. The company has raised $25M to date and is advancing three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma. It plans to advance a development candidate toward IND filing within two years.FinSMEsShennon Biotechnologies Raises $12M in FundingShennon Biotechnologies raised $12M in funding, bringing its total to $25M. The San Francisco-based biotech will use the funds to develop its integrated technology platform and advance its oncology pipeline, which includes three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma.Business Wire BlogShennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12M in financing and appointed Cyril Konto as CEO, with founder Li Sun moving to president and CTO. The company has raised $25M to date and is advancing three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma. It plans to advance a development candidate toward IND filing and Phase 1 within two years.Venture Capital Access OnlinePhoenixAI Raises $80M Series B Led by Sky9 Capital to Power the Agentic AI DatabasePhoenixAI announced an $80 million Series B funding round led by Sky9 Capital, with participation from Atypical Ventures and Olive Technology Ventures. The funds will accelerate development of its AI-native database, expand go-to-market initiatives, and deepen governance for regulated industries. The company's database is used in production by AppLovin, Coinbase, Conductor, and Demandbase.FinSMEsPhoenixAI Raises $80M Series B FundingPhoenixAI, a Menlo Park-based company developing an agentic AI database, raised $80M in Series B funding led by Sky9 Capital. The company will use the funds to accelerate development of its AI-native database, expand go-to-market initiatives, and deepen governance for regulated industries.VC News DailyPhoenixAI Secures $80M Series B RoundPhoenixAI, an AI-native database company based in Menlo Park, California, announced an $80 million Series B funding round led by Sky9 Capital, with participation from Atypical Ventures and Olive Technology Ventures. The company will use the proceeds to accelerate development of its Agentic AI Database platform, expand go-to-market initiatives, and deepen governance capabilities for regulated industries. The platform provides autonomous AI agents with sub-second access to live enterprise data at massive scale, unifying real-time and at-rest data in a single AI-native engine.PandailySEEKOO Raises Tens of Millions, Launches Multi-Agent Video Platform Anijam.aiSEEKOO, a Hangzhou-based video AI startup, raised tens of millions in a co-led round from Vision+ Capital, Miracle Plus, and Atypical Ventures. Its Anijam.ai platform attracted over a thousand paying users in two weeks, with more than half of content created from mobile devices.36kr"Cursor" for Video Creation: Anijam Revolutionizes Animation Creation ProcessAnijam, an AI video agent for animation creation, lets users generate full videos from natural-language prompts, including character and storyboard design. It has raised tens of millions of dollars and offers a tiered subscription from $25 to $60. The company plans to expand beyond animation and shift to a 'pay by results' model as costs fall.